Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)

CompletedOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
Leukemia, B-Cell, Chronic
Interventions
DRUG

Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)

"Descriptive statistical methods applied for the whole study cohort and for subgroups according to QoL and the correlation of the following parameters: Age, Sex, Stage of disease, Time from first B-CLL diagnosis, number of previous B-CLL treatments, Reason of starting of the new B-CLL treatment (progression disease, relapse, no-response to the previous treatment, previous treatment toxicity), Therapeutic Regimen (Day Hospital, Hospital Admission, etc.), Type of Centre, B-CLL treatment lasting, Response to B-CLL treatment.~QoL at baseline, Change in QoL over time evaluated using an analysis of Variance."

Trial Locations (1)

Unknown

Many Locations

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00344825 - Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL) | Biotech Hunter | Biotech Hunter